Daun Jung

ORCID: 0000-0002-3507-9826
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • Cancer Research and Treatments
  • 3D Printing in Biomedical Research
  • Immune cells in cancer
  • Cancer Cells and Metastasis
  • CAR-T cell therapy research
  • Pluripotent Stem Cells Research
  • interferon and immune responses
  • Mechanisms of cancer metastasis
  • Reproductive System and Pregnancy
  • Hedgehog Signaling Pathway Studies
  • T-cell and B-cell Immunology
  • Kruppel-like factors research
  • Glioma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Metabolomics and Mass Spectrometry Studies

CHA Bundang Medical Center
2021-2025

CHA University
2021-2025

Patient-derived xenograft (PDX) models are powerful tools in cancer research, offering an accurate platform for evaluating treatment efficacy and predicting responsiveness. However, these necessitate surgical techniques tumor tissue transplantation face challenges with non-uniform growth among animals. To address issues, we attempted to develop a new PDX modeling method using high-grade serous ovarian (HGSC), fatal disease 5-year survival rate of 29%, which requires personalized research due...

10.3390/cells14050325 article EN cc-by Cells 2025-02-21

A cancer-associated fibroblasts (CAFs) are the most important players that modulate tumor aggressiveness. In this study, we aimed to identify CAF-related genes in ovarian serous carcinomas (OSC) account for high incidence and mortality of cancers (OCs) develop therapeutic targets microenvironment modulation. Here, performed a microarray analysis CAFs isolated from three metastatic nonmetastatic OSC tissues compared their gene expression profiles. Among increased (mCAFs), GLIS1 (Glis Family...

10.3390/ijms23042218 article EN International Journal of Molecular Sciences 2022-02-17

Recurrent glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor that resistant to existing treatments. Recently, we reported activated autologous natural killer (NK) cell therapeutics induced marked increase in survival of some patients with recurrent GBM.To identify biomarkers predict responsiveness NK therapeutics, examined immune profiles tissues using NanoString nCounter analysis and compared the between 5 responders 7 non-responders. Through three-step data...

10.1186/s13578-023-00961-4 article EN cc-by Cell & Bioscience 2023-01-24

Abstract Background Recently, allogeneic natural killer (NK) cells have gained considerable attention as promising immunotherapeutic tools due to their unique biological functions and characteristics. Although many NK expansion strategies been reported previously, a deeper understanding of cryopreserved is needed for specific therapeutic approaches. Methods We isolated CD3 − CD56 + primary (pNK) from healthy donors expanded them ex vivo using GMP-compliant method without any feeder generate...

10.1186/s13046-021-02089-0 article EN cc-by Journal of Experimental & Clinical Cancer Research 2021-10-23

Allogeneic natural killer (NK) cell therapy has been effective in treating cancer. Many studies have tested NK using human pluripotent stem cells (hPSCs). However, the impacts of origin PSC-NK on competence are unclear. In this study, several types hPSCs, including human-induced PSCs (hiPSCs) generated from CD34+, CD3-CD56+, and CD56- umbilical cord blood (UCB), three lines embryonic (hESCs, ES-1. ES-2 ES-3) MHC I knockout (B2M-KO)-ESCs were used to differentiate into their capacities...

10.3390/ijms25158209 article EN International Journal of Molecular Sciences 2024-07-27

Patient-derived xenograft (PDX) models are powerful tool in cancer research, offering a more accurate platform for evaluating the treatment efficacy and predicting responsiveness. However, these necessitate surgical techniques tumor tissue transplantation face challenges with non-uniform growth among animals. To address issues, we attempted to develop new PDX modeling method using high-grade serous ovarian (HGSC), fatal disease 5-year survival rate of 29%, that requires personalized research...

10.20944/preprints202412.1691.v1 preprint EN 2024-12-19

Abstract Background Recurrent glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor that resistant to existing treatments. Recently, we reported activated autologous natural killer (NK) cell therapeutics induced marked increase in survival of some patients with recurrent GBM. Methods To identify biomarkers predict responsiveness NK therapeutics, examined immune profiles tissues using NanoString nCounter analysis and compared the between 5 responders 7...

10.1101/2022.09.21.22280225 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2022-09-23
Coming Soon ...